Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation
Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation
复制标题
卡瑞利珠单抗对既往接受卡瑞利珠单抗和微波消融治疗的非小细胞肺癌患者的再挑战
DOI：
10.4103/jcrt.jcrt_798_20
复制
发表时间：
2020-09-01
影响因子：
1.3
通讯作者：
Ye, Xin
中科院分区：
文献类型：
--
作者：
Wei, Zhigang;Yang, Xia;Ye, Xin
Camrelizumab是一种程序性死亡受体-1抑制剂，最初在中国开发，用于治疗难治性淋巴瘤。它对非小细胞肺癌患者也有效。然而，之前未报告camrelizumab的再激发。我们报告了2例既往接受微波消融（MWA）和camrelizumab治疗的患者接受camrelizumab治疗的再激发。尽管达到了客观缓解，但由于发生免疫相关性肺炎（IRP），停止了camrelizumab治疗。患者从IRP中恢复后，重新开始camrelizumab治疗。更严重的IRP的复发需要额外的皮质类固醇治疗。在接受MWA + camrelizumab方案治疗并发生IRP的患者中，camrelizumab的再激发应谨慎。
Camrelizumab is a programmed death receptor-1 inhibitor originally developed in China for the treatment of refractory lymphoma. It has also been effective in non-small-cell lung cancer patients. However, the rechallenge of camrelizumab was not reported previously. We report the rechallenge of camrelizumab therapy in two patients previously treated with microwave ablation (MWA) and camrelizumab. Although objective responses were achieved, camrelizumab therapy was discontinued because of the development of immune-related pneumonia (IRP). Treatment with camrelizumab was reinitiated after the patients recovered from IRP. The reoccurrence of more severe IRP necessitated additional corticosteroid therapy. The rechallenge of camrelizumab in patients treated with MWA plus camrelizumab regimen and who developed IRP should be cautious.